Inovio Pharmaceuticals Inc (NASDAQ: INO) is off to an incredibly strong day in the market today, and for good reason. The company released results with regard to its HIV Vaccine, showing a nearly 100% immune response rate. Of course, this led to excitement among investors, pushing the stock upward and prompting our partners at Trade Ideas to alert us to the gains. At the moment (8:24), INO is trading at $11.04 per share after a gain of $3.91 per share (54.84%) thus far today.
INO Gains On HIV Vaccine Results
As mentioned above, Inovio Pharmaceuticals is having an incredibly strong day in the market today after announcing that its HIV vaccine, known as PENNVAX®-GP, produced a very strong immune response rate in clinical subjects.
In a press release early this morning, INO said that 71 out of 76 evaluable vaccinated participants showed a CD4+ or CD8+ cellular immune response to at least one of the vaccine antigens. 62 out of 66 of the treated individuals also demonstrated an env specific body response. On the placebo arm, no response was seen on the cellular or antibody level.
According to the release, among the evaluated participants that received PENNVAX-GP and IL-12 via IM vaccination, 100% demonstrated a cellular response and 90% demonstrated an env specific antibody response. In a statement, Dr. J. Joseph Kim, President and CEO at INO, had the following to offer:
“These results are among the highest ever responses we’ve seen with an HIV vaccine, and they are remarkably consistent with our recent data reported from our Ebola, Zika and MERS clinical trials in terms of demonstrating nearly 100% vaccine response rates with very favorable safety profile. Furthermore, our newer and more tolerable intradermal vaccine delivery device showed that we can elicity very high immune responses at a much lower dose. We look forward to advancing PENNVAX-GP into later-stage clinical development with our partners and collaborators.”
Stop wasting your time! Find winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on INO. In particular, we’re interested in watching continued work surrounding PENNVAX-GP as the vaccine seems to be overwhelmingly effective. We’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!